百济神州(BGNE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BGNE 百济神州

休市中 04-26 16:00:00 EDT

153.58

+5.02

+3.38%

盘后153.58

+0.000.00%

16:06 EDT

最高154.47	最低150.73	成交量20.85万
今开152.11	昨收148.56	日振幅2.52%
总市值160.48亿	流通市值90.01亿	总股本1.04亿
成交额3,197万	换手率0.36%	流通股本5,861万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"BGNE","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":153.58,"timestamp":1714161600000,"preClose":148.56,"halted":0,"volume":208460,"hourTrading":{"tag":"盘后","latestPrice":153.58,"preClose":153.58,"latestTime":"16:06 EDT","volume":3334,"amount":512035.72,"timestamp":1714161989730},"delay":0,"floatShares":58607752,"shares":104490318,"eps":-8.446508,"marketStatus":"休市中","marketStatusCode":7,"change":5.02,"latestTime":"04-26 16:00:00 EDT","open":152.11,"high":154.47,"low":150.726,"amount":31965754.6194,"amplitude":0.025202,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-8.446508,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1714377600000},"adr":1,"adjPreClose":148.56,"adrRate":13,"postHourTrading":{"tag":"盘后","latestPrice":153.58,"preClose":153.58,"latestTime":"16:06 EDT","volume":3334,"amount":512035.72,"timestamp":1714161989730},"volumeRatio":0.8158125019505892},"requestUrl":"/m/hq/s/BGNE/tweets","defaultTab":"tweets","newsList":[{"id":"2430798726","title":"百济神州亏损缩窄50%，核心产品成国内首个“十亿美元分子”","url":"https://stock-news.laohu8.com/highlight/detail?id=2430798726","media":"蓝鲸财经","top":-1,"share":"https://www.laohu8.com/m/news/2430798726?lang=zh_cn&edition=full","pubTime":"2024-04-27 14:34","pubTimestamp":1714199648,"startTime":"0","endTime":"0","summary":"2024年4月26日，百济神州发布A股2023年年度报告。2023年，百济神州全球营业收入174.23亿元，同比增长82.1%，报告期内公司归属净利润同比减亏，对应实现的归属净利润约为-67.16亿元，同比增长50.77%。财报显示，2023年其核心产品泽布替尼作为中国创新药出海的代表，全球销售额较上年同期了138.7%，达到91.38亿元，成为国内首个年销售额超过十亿美元的国产创新药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/231144","is_publish_highlight":false,"gpt_icon":0},{"id":"2430376191","title":"百济神州：2023年度净利润约-67.16亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430376191","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2430376191?lang=zh_cn&edition=full","pubTime":"2024-04-27 11:43","pubTimestamp":1714189402,"startTime":"0","endTime":"0","summary":"百济神州（SH688235，收盘价：130.77元）4月27日发布年度业绩报告称，2023年营业收入约174.23亿元，同比增加82.13%；归属于上市公司股东的净利润亏损约67.16亿元；基本每股收益亏损4.95元。2022年同期营业收入约95.66亿元；归属于上市公司股东的净利润亏损约136.42亿元；基本每股收益亏损10.18元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202404273062218596.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404273062218596.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430646727","title":"百济神州2023年实现营收174.23亿元 同比增长82.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430646727","media":"经济参考网","top":-1,"share":"https://www.laohu8.com/m/news/2430646727?lang=zh_cn&edition=full","pubTime":"2024-04-27 11:42","pubTimestamp":1714189365,"startTime":"0","endTime":"0","summary":"4月26日，百济神州（688235.SH）发布A股2023年报。公司去年实现营业收入174.23亿元，同比增长82.1%。全年产品收入再创突破，达155.04亿元，同比增长82.8%。产品收入增长强劲2023年，百济神州加速全球业务发展，以两款自主研发药物为增长引擎，商业化领先优势进一步扩大。百济神州产品收入大幅增长的驱动力，主要来自BTK抑制剂百悦泽?（泽布替尼）的全球放量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404273062230389.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430763350","title":"百济神州2023年净亏损缩窄约50% 研发投入是业内平均水平的8倍，仍然坚持“去CRO”","url":"https://stock-news.laohu8.com/highlight/detail?id=2430763350","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2430763350?lang=zh_cn&edition=full","pubTime":"2024-04-27 10:55","pubTimestamp":1714186511,"startTime":"0","endTime":"0","summary":"百济神州（688235.SH，股价130.77元，市值1776.35亿元）甩开恒瑞医药（600276.SH，股价45.61元，市值2909.46亿元），继续稳坐国内创新药“一哥”交椅。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202404273062194250.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404273062194250.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430785433","title":"图解百济神州年报：第四季度单季净利润同比增11.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430785433","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430785433?lang=zh_cn&edition=full","pubTime":"2024-04-27 01:05","pubTimestamp":1714151133,"startTime":"0","endTime":"0","summary":"证券之星消息，百济神州2023年年报显示，公司主营收入174.23亿元，同比上升82.13%；归母净利润-67.16亿元，同比上升50.77%；扣非净利润-96.82亿元，同比上升29.97%；其中2023年第四季度，公司单季度主营收入45.48亿元，同比上升68.6%；单季度归母净利润-28.38亿元，同比上升11.55%；单季度扣非净利润-28.99亿元，同比上升11.52%；负债率38.95%，投资收益1.67亿元，财务费用1.97亿元，毛利率84.57%。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042701053687b4808c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042701053687b4808c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430427294","title":"百济神州(688235.SH)发2023年度业绩，营收大涨82.13%至174.23亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430427294","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430427294?lang=zh_cn&edition=full","pubTime":"2024-04-26 21:19","pubTimestamp":1714137588,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州 发布2023年年度报告，报告期内公司实现营业收入174.23亿元，同比大涨82.13%;归属于上市公司股东的净亏损大幅收窄至67.16亿元。百泽安已在中国获批用于12项适应症，其中11项适应症已纳入国家医保目录，其广泛的全球临床布局包括在超过30个国家和地区入组受试者超过13,000人。公司已重获百泽安开发、生产和商业化的全球权利，加强公司在实体肿瘤领域的全球产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1112378.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430293279","title":"百济神州发布A股2023年年报及负责任商业和可持续发展报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2430293279","media":"证券时报网","top":-1,"share":"https://www.laohu8.com/m/news/2430293279?lang=zh_cn&edition=full","pubTime":"2024-04-26 20:38","pubTimestamp":1714135122,"startTime":"0","endTime":"0","summary":"证券时报网讯，2024年4月26日晚间，百济神州（纳斯达克代码：BGNE；香港联交所代码：06160；上交所代码：688235.SH）发布A股2023年年度报告。2023年，百济神州营业收入达174.23亿元，同比增长82.1%。全年产品收入再创突破，达155.04亿元，同比增长82.8%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202404263061464814.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404263061464814.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430276988","title":"百济神州2023年净利亏损67.16亿元 同比减亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2430276988","media":"北京商报官方账号","top":-1,"share":"https://www.laohu8.com/m/news/2430276988?lang=zh_cn&edition=full","pubTime":"2024-04-26 20:18","pubTimestamp":1714133932,"startTime":"0","endTime":"0","summary":"北京商报讯（记者 丁宁）4月26日晚间，百济神州（688235）发布2023年年报，报告期内公司归属净利润同比减亏。财务数据显示，2023年，百济神州实现营业收入约为174.23亿元，同比增长82.13%；对应实现的归属净利润约为-67.16亿元，同比增长50.77%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404262020038b572a16&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404262020038b572a16&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430760012","title":"百济神州2023年产品收入达155亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430760012","media":"北京商报","top":-1,"share":"https://www.laohu8.com/m/news/2430760012?lang=zh_cn&edition=full","pubTime":"2024-04-26 20:14","pubTimestamp":1714133678,"startTime":"0","endTime":"0","summary":"北京商报讯（记者 姚倩）4月26日，百济神州发布A股2023年年度报告。2023年，百济神州营业收入达174.23亿元，同比增长82.1%。其中，产品收入达155.04亿元，同比增长82.8%。据此前披露的美股业绩，公司经调整经营亏损同比收窄47%。百济神州产品收入大幅增长的驱动力，主要来自BTK抑制剂泽布替尼的全球放量。2023年，泽布替尼全球销售额总计91.38亿元，同比增长138.7%。据此前披露的美股业绩，泽布替尼全球销售额达13亿美元，这是其自2019年在美上市以来，年销售额首次突破10亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042620144087b39400&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042620144087b39400&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430754002","title":"百济神州(06160)2023年可持续发展报告：以负责任运营 推动全球健康公平","url":"https://stock-news.laohu8.com/highlight/detail?id=2430754002","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430754002?lang=zh_cn&edition=full","pubTime":"2024-04-26 19:54","pubTimestamp":1714132457,"startTime":"0","endTime":"0","summary":"2023年，百济神州营业收入达174.23亿元，同比增长82.1%。此外，百济神州同期发布了《2023年负责任商业和可持续发展》报告，披露了公司在推进全球健康、赋能员工、可持续创新，以及负责任运营四大重点领域的实践和未来规划。报告显示，2023年，百济神州推进并实现了多项战略目标，包括制定了全球健康公平战略，扩大了面向全球患者的药物可及性，设立首个定量气候目标，并提升了女性领导层的比例。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042620131387b392c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042620131387b392c5&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430278267","title":"百济神州：2023年净利润亏损67.16亿元，营业收入174.23亿元，同比增长82.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430278267","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430278267?lang=zh_cn&edition=full","pubTime":"2024-04-26 19:44","pubTimestamp":1714131891,"startTime":"0","endTime":"0","summary":"百济神州公告称，2023年度，公司实现营业收入174.23亿元，同比增长82.13%，归属于上市公司股东的净利润亏损67.16亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261944558b57100a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261944558b57100a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430422945","title":"百济神州发布《2023年负责任商业和可持续发展》报告，公布全球进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2430422945","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2430422945?lang=zh_cn&edition=full","pubTime":"2024-04-26 18:00","pubTimestamp":1714125600,"startTime":"0","endTime":"0","summary":"\" 百济神州的负责任商业和可持续发展战略围绕四大重点领域：推进全球健康、赋能员工、可持续创新和负责任运营。自2021年起，百济神州致力于在各领域设定目标，并每年报告进展。主要成果 百济神州《负责任商业和可持续发展》报告重点介绍了公司2023年以来取得的主要成果，其中包括：  副总裁及以上职位的女性比例从2022年的33%提高至2023年的38%。启动供应商管理计划，这将有助于百济神州在2025年前完成\"范围三\"的目标设定。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4398483_ZH98483_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430293538","title":"百济神州4月25日获南向资金加仓54.75万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430293538","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430293538?lang=zh_cn&edition=full","pubTime":"2024-04-26 09:31","pubTimestamp":1714095092,"startTime":"0","endTime":"0","summary":"4月25日, 南向资金增持百济神州54.75万股，连续6日增持。截止当日收盘，港股通共持有百济神州5343.80万股，占流通股3.92%。百济神州近5个交易日上涨13.64%，港股通累计增持120.33万股；近20个交易日下跌1.69%，港股通累计增持267.39万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404260943328b54fb46&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404260943328b54fb46&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430708238","title":"百济神州上涨5.32%，报151.78美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430708238","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430708238?lang=zh_cn&edition=full","pubTime":"2024-04-25 23:29","pubTimestamp":1714058941,"startTime":"0","endTime":"0","summary":"4月25日，百济神州(BGNE)盘中上涨5.32%，截至23:29，报151.78美元/股，成交1699.37万美元。财务数据显示，截至2023年12月31日，百济神州收入总额24.59亿美元，同比增长73.65%；归母净利润-8.82亿美元，同比增长56.0%。大事提醒：5月2日，百济神州将披露2024财年一季报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/25232940415847.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430160238","title":"百济神州盘中异动 早盘股价大涨5.32%报151.78美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430160238","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430160238?lang=zh_cn&edition=full","pubTime":"2024-04-25 23:28","pubTimestamp":1714058922,"startTime":"0","endTime":"0","summary":"北京时间2024年04月25日23时28分，百济神州股票出现波动，股价急速上涨5.32%。截至发稿，该股报151.78美元/股，成交量11.4778万股，换手率0.11%，振幅3.90%。机构评级方面，在所有25家参与评级的机构中，92%的券商给予买入建议，8%的券商给予持有建议，无券商给予卖出建议。百济神州股票所在的生物技术行业中，整体跌幅为1.64%。百济神州公司简介：百济神州有限公司是一家处于商业阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042523284287e83cc4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042523284287e83cc4&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430448021","title":"百济神州(06160)上涨5.06%，报91.4元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430448021","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430448021?lang=zh_cn&edition=full","pubTime":"2024-04-25 11:02","pubTimestamp":1714014178,"startTime":"0","endTime":"0","summary":"4月25日，百济神州(06160)盘中上涨5.06%，截至11:02，报91.4元/股，成交8014.37万元。百济神州有限公司是一家专注于开发和商业化用于治疗癌症的创新型分子靶向和肿瘤免疫治疗药物的生物技术公司。公司拥有包括六种内部开发的临床阶段候选药物和五种获得授权许可的药物在内的广泛产品组合，以及超过1300名员工的全球团队。截至2023年年报，百济神州营业总收入174.15亿元、净利润-62.45亿元。5月8日，百济神州将披露2024财年一季报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/25110240400362.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430414264","title":"南向资金4月24日净买入百济神州14.56万股 连续5日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2430414264","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430414264?lang=zh_cn&edition=full","pubTime":"2024-04-25 09:31","pubTimestamp":1714008677,"startTime":"0","endTime":"0","summary":"4月24日, 南向资金增持百济神州14.56万股，连续5日增持。截止当日收盘，港股通共持有百济神州5289.05万股，占流通股3.88%。港股通增持金额前五个股分别为腾讯控股、中国银行、中国财险、中国石油化工股份、中国移动。百济神州近5个交易日上涨7.34%，港股通累计增持66.73万股；近20个交易日下跌5.90%，港股通累计增持239.01万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404250946028b50f335&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404250946028b50f335&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429456166","title":"百济神州上涨3.23%，报143.48美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2429456166","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2429456166?lang=zh_cn&edition=full","pubTime":"2024-04-24 21:30","pubTimestamp":1713965432,"startTime":"0","endTime":"0","summary":"4月24日，百济神州(BGNE)开盘上涨3.23%，截至21:30，报143.48美元/股，成交76.59万美元。财务数据显示，截至2023年12月31日，百济神州收入总额24.59亿美元，同比增长73.65%；归母净利润-8.82亿美元，同比增长56.0%。大事提醒：5月2日，百济神州将披露2024财年一季报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/24213040392874.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429253177","title":"港股异动 | 百济神州(06160)涨近4% 替雷利珠单抗获欧盟委员会批准用于治疗非小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2429253177","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429253177?lang=zh_cn&edition=full","pubTime":"2024-04-24 11:31","pubTimestamp":1713929479,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百济神州(06160)涨近4%，截至发稿，涨3.54%，报84.9港元，成交额4813.84万港元。消息面上，百济神州宣布欧盟委员会（EC）已批准替雷利珠单抗用于三项非小细胞肺癌（NSCLC）适应症的一线及二线治疗。被批准用于上述NSCLC适应症的替雷利珠单抗商品名为TIZVENI®。公司计划将NSCLC适应症与ESCC二线治疗适应症统一合并至商品名TEVIMBRA®下，TEVIMBRA®将于今年晚些时候在首批欧盟国家上市。目前，百济神州已启动超过17项替雷利珠单抗的潜在注册性研究，其中，11项3期随机对照研究和4项2期研究均获得积极数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1108261.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429419022","title":"百济神州盘中异动 早盘快速拉升5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429419022","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429419022?lang=zh_cn&edition=full","pubTime":"2024-04-23 21:30","pubTimestamp":1713879042,"startTime":"0","endTime":"0","summary":"北京时间2024年04月23日21时30分，百济神州股票出现异动，股价急速拉升5.17%。截至发稿，该股报137.71美元/股，成交量1962股，换手率0.00%，振幅0.00%。机构评级方面，在所有25家参与评级的机构中，92%的券商给予买入建议，8%的券商给予持有建议，无券商给予卖出建议。百济神州股票所在的生物技术行业中，整体涨幅为1.18%。百济神州公司简介：百济神州有限公司是一家处于商业阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404232130437922aeaa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404232130437922aeaa&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beigene.cn","stockEarnings":[{"period":"1week","weight":0.1858},{"period":"1month","weight":-0.0097},{"period":"3month","weight":-0.0514},{"period":"6month","weight":-0.099},{"period":"1year","weight":-0.3989},{"period":"ytd","weight":-0.1485}],"compareEarnings":[{"period":"1week","weight":0.0265},{"period":"1month","weight":-0.0285},{"period":"3month","weight":0.0428},{"period":"6month","weight":0.2376},{"period":"1year","weight":0.2324},{"period":"ytd","weight":0.0693}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"　　百济神州有限公司是一家全球性、商业阶段的生物科技公司，专注于研究、开发、生产以及商业化创新型药物，主要产品百悦泽（（BRUKINSA），BTK抑制剂）、百泽安（抗PD-1单抗）、帕米帕利。公司自主研发产品BRUKINSA（百悦泽）实现了中国原研新药出海的“零突破”，并凭借这一里程碑式的突破于2020年获得由中国健康产业创新平台颁发的“药品创新奇璞奖”。同年，公司凭借自主研发产品百泽安获得上海市张江科学城建设管理办公室颁发的“2019年度张江科学城优秀企业创新成果奖”。此外，公司作为承担单位进行了5项国家级科研项目，并在核心期刊上发表了34篇学术论文。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.062331},{"month":2,"riseRate":0.625,"avgChangeRate":0.017001},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.028933},{"month":4,"riseRate":0.444444,"avgChangeRate":0.028444},{"month":5,"riseRate":0.5,"avgChangeRate":-0.012888},{"month":6,"riseRate":0.625,"avgChangeRate":0.022561},{"month":7,"riseRate":0.75,"avgChangeRate":0.132564},{"month":8,"riseRate":0.5,"avgChangeRate":0.021799},{"month":9,"riseRate":0.5,"avgChangeRate":0.051436},{"month":10,"riseRate":0.625,"avgChangeRate":0.017618},{"month":11,"riseRate":0.5,"avgChangeRate":0.059889},{"month":12,"riseRate":0.375,"avgChangeRate":-0.023463}],"exchange":"NASDAQ","name":"百济神州","nameEN":"BeiGene"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(BGNE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(BGNE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,BGNE,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(BGNE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(BGNE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}